Completed Graft vs Host Disease trials: Trial Insights

Filters: Condition: Graft vs Host Disease Status: Completed Clear all

347 trials match Source: ClinicalTrials.gov registrations

Trials started per year
Category	Trials
2000	11
2001	8
2002	15
2003	14
2004	20
2005	17
2006	13
2007	11
2008	20
2009	13
2010	15
2011	15
2012	12
2013	15
2014	16
2015	16
2016	14
2017	16
2018	18
2019	8
2020	8
2021	8
2022	3
2023	6

Trials by status
Category	Trials
Completed	347

Top lead sponsors
Category	Trials
National Heart, Lung, and Blood Institute (NHLBI)	19
Dana-Farber Cancer Institute	16
Fred Hutchinson Cancer Center	16
M.D. Anderson Cancer Center	12
H. Lee Moffitt Cancer Center and Research Institute	11
National Cancer Institute (NCI)	9
Novartis Pharmaceuticals	8
University of Michigan Rogel Cancer Center	7
Wyeth is now a wholly owned subsidiary of Pfizer	7
Roswell Park Cancer Institute	6

Top conditions
Category	Trials
Graft vs Host Disease	347
Leukemia	59
Myelodysplastic Syndromes	59
Precursor Cell Lymphoblastic Leukemia-Lymphoma	58
Leukemia, Myeloid, Acute	54
Lymphoma, Non-Hodgkin	44
Leukemia, Lymphocytic, Chronic, B-Cell	43
Hodgkin Disease	41
Hematologic Neoplasms	39
Lymphoma	39

Trials

Showing 76 to 100 of 347. Each trial links to its page on Pharma Observatory.

Early Detection of Mucosal Abnormalities in Graft-versus-host Disease NCT02707354Not applicableCompletedNantes University HospitalStarted 2016
Single-centre Study of Everolimus as GvHD Prophylaxis After Post-Transplantation Cyclophosphamide After Allogeneic SCT NCT02812940Phase 2CompletedUniversity of CologneStarted 2016
Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD NCT02525029Phase 1/2CompletedMasonic Cancer Center, University of MinnesotaStarted 2016
Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention NCT02588339Phase 2CompletedH. Lee Moffitt Cancer Center and Research InstituteStarted 2016
Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation NCT02683525Phase 2CompletedSherif S. FaragStarted 2016
SCHEDULE Follow Up Visit 5-7 yr NCT02864706Phase 4CompletedNovartis PharmaceuticalsStarted 2016
Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD NCT02614612Phase 1CompletedIncyte CorporationStarted 2015
Nutrition and Outcomes of Hematopoietic Cell Transplantation (HCT) NCT03419078ObservationalCompletedImperial College Healthcare NHS TrustStarted 2015
Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor NCT02500550Phase 2CompletedKiadis PharmaStarted 2015
Irradiated Blood Versus Non Irradiated Blood Transfusions in Craniosynostosis Repair NCT02483702Not applicableCompletedValley Anesthesiology ConsultantsStarted 2015
Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT NCT02634294Phase 2/3CompletedShanghai General Hospital, Shanghai Jiao Tong University School of MedicineStarted 2015
Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention NCT02423915Phase 1CompletedM.D. Anderson Cancer CenterStarted 2015
Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders NCT02484053Phase 1CompletedBaylor College of MedicineStarted 2015
Comparison of Gut Microbiota, Inflammation and Symptoms Following Allogeneic HSCT NCT02398708ObservationalCompletedUniversity of FloridaStarted 2015
Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation NCT02342613Phase 1CompletedSidney Kimmel Comprehensive Cancer Center at Johns HopkinsStarted 2015
Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major NCT02342145Phase 4CompletedZhongming ZhangStarted 2015
Cognitive Function and Patient-Reported Quality of Life Outcomes Investigation in Patients Taking Vorinostat NCT02409134ObservationalCompletedSung Choi, M.D.Started 2015
Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation NCT02945176Not applicableCompletedImplandata Ophthalmic Products GmbHStarted 2015
Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases NCT02248597Phase 2CompletedWake Forest University Health SciencesStarted 2015
Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD NCT02176031Phase 2CompletedDana-Farber Cancer InstituteStarted 2015
BMT Autologous MSCs for GvHD NCT02359929Phase 1CompletedEmory UniversityStarted 2015
Allogenic Bone Marrow Mesenchymal Stem Cells Infusion in Patients With Steroid-refractory GVHD NCT02824653Phase 1/2CompletedNational Institute of Blood and Marrow Transplant (NIBMT), PakistanStarted 2015
Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant NCT01790568Phase 2CompletedUniversity of Michigan Rogel Cancer CenterStarted 2014
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies NCT02145403Phase 1/2CompletedUniversity of Michigan Rogel Cancer CenterStarted 2014
Mesenchymal Stem Cell Infusion in Haploidentical Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies NCT03106662Phase 3CompletedAnkara UniversityStarted 2014

247 more trials match. See them on Pharma Observatory

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.

Visit Pharma Observatory